KR920701127A - 단백질에 금속 이온을 부착하기 위한 킬레이트제 - Google Patents

단백질에 금속 이온을 부착하기 위한 킬레이트제

Info

Publication number
KR920701127A
KR920701127A KR1019910700100A KR910700100A KR920701127A KR 920701127 A KR920701127 A KR 920701127A KR 1019910700100 A KR1019910700100 A KR 1019910700100A KR 910700100 A KR910700100 A KR 910700100A KR 920701127 A KR920701127 A KR 920701127A
Authority
KR
South Korea
Prior art keywords
complex
chelating agent
bound
polypeptide
coo
Prior art date
Application number
KR1019910700100A
Other languages
English (en)
Other versions
KR100199892B1 (ko
Inventor
라마스와미 서브 라마니안
Original Assignee
에프.지.엠.헤르만스.에이.지.제이.베르미렌
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠.헤르만스.에이.지.제이.베르미렌, 악조 엔.브이. filed Critical 에프.지.엠.헤르만스.에이.지.제이.베르미렌
Publication of KR920701127A publication Critical patent/KR920701127A/ko
Priority to KR1019980707073A priority Critical patent/KR100186799B1/ko
Application granted granted Critical
Publication of KR100199892B1 publication Critical patent/KR100199892B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/20—Diazonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

내용 없음

Description

단백질에 금속 이온을 부착하기 위한 킬레이트제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
본 발명의 이작용기 킬레이트가 제1도에서 도시되어 있다. 제1도에서, “a”는 LiLo1이고, “b”는 LiLo2이고, “c”는 DICAP이고, “d”는 IDAC이다. 제2도는 금속 결합 킬레이트제, DICAP, IDAC및 LiLo를 얻기 위한 합성을 설명하고 있다. 제3도는 37℃에서 인산염 완충염(0.05M,pH 7.2)에서 인듐-111표시 HSA-LiLo1과 HSA-DTPA의 안정성들을 비교하고 있다.

Claims (32)

  1. 하기 일반식의 킬레이트제 DICAP:
  2. 제1항의 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  3. 제1항의 킬레이트제에 결합된 금속을 포함하는 착물.
  4. 제1항의 킬레이트제에 결합된 폴리펩타이드를 포함하는 착물.
  5. 제4항에 있어서, 폴리펩타이드가 항체인 착물.
  6. 제4항에 있어서, 킬레이트제에 결합된 방사적 핵종을 포함하는 착물.
  7. 하기 일반식의 킬레이트제 LiLo :
    상기식에서, n은 1또는 2이다.
  8. 제7항의 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  9. 제7항의 킬레이트제에 결합된 금속을 포함하는 착물.
  10. 제7항의 킬레이트제에 결합된 폴리펩타이드를 포함하는 착물.
  11. 제10항에 있어서, 폴리펩타이드가 항체인 착물.
  12. 제10항에 있어서, 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  13. 하기 일반식의 킬레이트제 IDAC:
  14. 제13항의 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  15. 제13항의 킬레이트제에 결합된 금속을 포함하는 착물.
  16. 제13항의 킬레이트제에 결합된 폴리펩타이드를 포함하는 착물.
  17. 제16항에 있어서, 폴리펩타이드가 항체인 착물.
  18. 제16항에 있어서, 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  19. 하기 일반식의 성상으로 가지난리간드 킬레이트제:
    상기식에서, X는 COO-및 CH2-N-Y로 이루어진 그룹에서 선택되고, Y는 CH2-COO-, 또는 원하는 수의 COO-결합부위가 n열의 N에서 이용될 수 있을때까지의 CH2-N-Y의 그밖의 반복이고, N의 열은 2이고, N의 최종열에서 N의 수는 2(n-1)이고, 결합을 위한 COO-의 수는 2n이다.
  20. 제19항의 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  21. 제19항의 킬레이트제에 결합된 금속을 포함하는 착물.
  22. 제19항의 킬레이트제에 결합된 폴리펩타이드를 포함하는 착물.
  23. 제22항에 있어서, 폴리펩타이드가 항체인 착물.
  24. 제22항에 있어서, 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  25. 제19항에 있어서, n이 5이고, 결합을 위한 COO-의 수가 32인, 성상으로 가지난 리간드 킬레이트제.
  26. 하기 일반식의 성상으로 가지난 LiLo 리간드:
    상기식에서 Z는
    및
    로 이루어진 그룹에서 선택된 것이고
    A는
    또는 원하는 수의 COO-결합부위가 n열의 N에서 이용될 수 있을때까지의
    의 그밖의 반복이고, 결합을 위한 COO-의 수는 2(M+1)이다.
  27. 제26항의 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  28. 제26항의 킬레이트제에 결합된 금속을 포함하는 착물.
  29. 제26항의 킬레이트제에 결합된 폴리펩타이드를 포함하는 착물.
  30. 제29항에 있어서, 폴리펩타이드가 항체인 착물.
  31. 제29항에 있어서, 킬레이트제에 결합된 방사적핵종을 포함하는 착물.
  32. 제26항에 있어서, n이 5이고, 결합을 위한 COO-의 수가 64인 성상으로 가지난 LiLo 리간드.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700100A 1989-05-26 1991-01-25 단백질에 금속 이온을 부착하기 위한 킬레이트제 KR100199892B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980707073A KR100186799B1 (ko) 1989-05-26 1998-09-08 단백질에 금속 이온을 부착하기 위한 킬레이트제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US358917 1982-03-17
US35891789A 1989-05-26 1989-05-26
US358,917 1989-05-26
PCT/US1990/002910 WO1990014881A2 (en) 1989-05-26 1990-05-23 Chelating agents for attaching metal ions to proteins
USPUS90/02910 1990-05-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019980707073A Division KR100186799B1 (ko) 1989-05-26 1998-09-08 단백질에 금속 이온을 부착하기 위한 킬레이트제

Publications (2)

Publication Number Publication Date
KR920701127A true KR920701127A (ko) 1992-08-11
KR100199892B1 KR100199892B1 (ko) 1999-06-15

Family

ID=23411575

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019910700100A KR100199892B1 (ko) 1989-05-26 1991-01-25 단백질에 금속 이온을 부착하기 위한 킬레이트제
KR1019980707073A KR100186799B1 (ko) 1989-05-26 1998-09-08 단백질에 금속 이온을 부착하기 위한 킬레이트제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019980707073A KR100186799B1 (ko) 1989-05-26 1998-09-08 단백질에 금속 이온을 부착하기 위한 킬레이트제

Country Status (13)

Country Link
EP (2) EP0661267A1 (ko)
JP (1) JP2865112B2 (ko)
KR (2) KR100199892B1 (ko)
AT (1) ATE128035T1 (ko)
AU (1) AU638757B2 (ko)
CA (1) CA2033086A1 (ko)
DE (1) DE69022542T2 (ko)
DK (1) DK0429644T3 (ko)
ES (1) ES2080160T3 (ko)
FI (1) FI104409B (ko)
IE (1) IE68411B1 (ko)
WO (1) WO1990014881A2 (ko)
ZA (1) ZA904047B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5808003A (en) * 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5292868A (en) * 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
CA2180662A1 (en) * 1994-01-07 1995-07-13 Ramaswamy Subramanian New polyaminocarboxylate chelators
GB9407812D0 (en) * 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
US5814521A (en) * 1995-10-06 1998-09-29 Bayer Corporation Metal ion determination by sandwich aggregation assay
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301395L (sv) * 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
ATE89743T1 (de) * 1986-08-18 1993-06-15 Dow Chemical Co Conjugate dichter sterne.

Also Published As

Publication number Publication date
IE901867L (en) 1990-11-26
DE69022542D1 (de) 1995-10-26
FI910329A0 (fi) 1991-01-22
EP0661267A1 (en) 1995-07-05
EP0429644A4 (en) 1991-11-21
JP2865112B2 (ja) 1999-03-08
JPH04500389A (ja) 1992-01-23
KR100186799B1 (ko) 1999-05-15
CA2033086A1 (en) 1990-11-27
DK0429644T3 (da) 1996-01-22
IE68411B1 (en) 1996-06-12
AU6427590A (en) 1991-01-07
EP0429644B1 (en) 1995-09-20
ES2080160T3 (es) 1996-02-01
DE69022542T2 (de) 1996-05-02
ZA904047B (en) 1991-09-25
FI104409B (fi) 2000-01-31
AU638757B2 (en) 1993-07-08
WO1990014881A2 (en) 1990-12-13
ATE128035T1 (de) 1995-10-15
WO1990014881A3 (en) 1991-01-24
KR100199892B1 (ko) 1999-06-15
EP0429644A1 (en) 1991-06-05

Similar Documents

Publication Publication Date Title
DK0417870T3 (da) Chelatdannere til kompleksbinding af radioaktive isotoper, metalkomplekser deraf samt anvendelsen deraf til diagnostik og terapi
DE68924383D1 (de) Ineinander dispergierte zwei-phasige Ferrit-Zusammensetzung.
ES8504668A1 (es) Procedimiento para la obtencion de preparados para realizar diagnosticos medicos.
DE3582961D1 (de) Platinkoordinationsverbindungen.
DE3486030D1 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
NZ220948A (en) Nickel-chelate resins, their preparation and use in chromatography for purifying proteins; and n-(omega-amino-1-carboxyalkyl)-iminodiacetic acid derivatives used to prepare the resins
DE69016900D1 (de) Analysator von Isotopenzusammensetzungen.
DE69433114D1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
IT8424009A0 (it) Composizioni analgesiche ed anti-infiammatorie migliorate, comprendente xantine e metodi di utilizzare le stesse.
IT7925778A0 (it) Preparato immunoglobulinico procedimento di preparazione di un contenente anticorpi somministrabile per via endovenosa e preparati cosi' ottenuti.
DE3587275D1 (de) Durch rehydratation bindbares aluminiumoxid.
FI841260A0 (fi) Immunoglobulinkonjugater.
KR920701127A (ko) 단백질에 금속 이온을 부착하기 위한 킬레이트제
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
DE3674352D1 (de) Lagerstabile praeparate von in wasser unloeslichen bis schwerloeslichen feststoffen.
ATE120233T1 (de) Monoklonale antikörper, b-spezifisch für apolipoprotein, die von zwei hybridomen erzeugt werden.
Nandedkar et al. Mn++ binding by plasma proteins
DE3762355D1 (de) Verbesserung der korrosionsbestaendigkeit von zirkonlegierungen.
RU93004696A (ru) Способ адсорбции с применением таннина
ATE180489T1 (de) Für leberzellkarzinom spezifisches onkogen
DE69431526D1 (de) Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
PT85992A (de) Verfahren zur bestimmung von anti-hiv, mittel dazu und ihre verwendung in diesem verfahren
KR950011467A (ko) 염증친화성 펩티드 및 그 펩티드를 함유한 방사성진단제
DE3485378D1 (de) Detergenszusammensetzungen, detergensfluessigkeiten und verfahren fuer ihre zubereitung.
DK0570575T3 (da) Bicykloazamakrocyklophosphonsyre, komplekser, konjugater, kontrastmidler og fremstilling heraf

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee